Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

March 22, 2013

Primary Completion Date

September 18, 2020

Study Completion Date

September 18, 2020

Conditions
Myeloma
Interventions
DRUG

Minocycline

200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.

OTHER

Placebo

200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).

BEHAVIORAL

Questionnaires

Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01793051 - Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | Biotech Hunter | Biotech Hunter